Ciluprevir

Ciluprevir (BILN 2061) is a specific and potent peptidomimetic inhibitor of the HCV NS3 protease with an IC50 of 3.0 nM.

Product Specifications

CAS Number

[300832-84-2]

Product Name Alternative

BILN 2061; BILN 2061ZW

UNSPSC

12352005

Hazard Statement

H302

Target

HCV; HCV Protease

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/ciluprevir.html

Solubility

10 mM in DMSO

Smiles

O=C1N2C[C@@H](C[C@]2(C(N[C@@]3(C[C@]3(/C=C\CCCCC[C@@H]1NC(OC4CCCC4)=O)[H])C(O)=O)=O)[H])OC5=CC(C6=CSC(NC(C)C)=N6)=NC7=CC(OC)=CC=C75

Molecular Formula

C40H50N6O8S

Molecular Weight

774.93

Precautions

P264-P270-P330-P501

References & Citations

[1]Llinàs-Brunet M, et al. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. J Med Chem. 2004 Mar 25;47 (7) :1605-8.|[2]Thibeault D, et al. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J Virol. 2004 Jul;78 (14) :7352-9.|[3]Lamarre D, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 2003 Nov 13;426 (6963) :186-9.|[4]Reiser M, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology. 2005 Apr;41 (4) :832-5.